Respiratory medicine · 2026
Efficacy of ambroxol hydrochloride and clenbuterol hydrochloride oral solution, its influencing factors, and its effect on quality of life in child patients with lower respiratory tract infections and symptoms of mucoid sputum.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhou Yunlian, Hu Bing, Liu Enmei, Ma Jinhai, Liu Changshan, Lu Quan, Dong Xiaoyan, Zi Huifen, Hao Chuangli, Lin Rongjun, Zheng Xiangrong, Li Bingfei, Chen Fenhua, Fang Mei, Tian Weimin, Zhuo Zhiqiang, Zhao Deyu, Zheng Yuejie, Yin Yong, Tang Qiuyu, Wu Liqun, Gu Li, Wu Jinzhun, He Liyi, Ai Tao, Liu Hanmin, Han Zhiying, Mo Yunbo, Tian Zhiliang, Chen Zhimin
Аннотация
OBJECTIVE: Ambroxol hydrochloride and clenbuterol hydrochloride oral solution (AHCHOS) is an agent with mucolytic and bronchodilator functions, but its clinical application in child patients with lower respiratory tract infections (LRTI) and symptoms of mucoid sputum needs more investigation. This study aimed to investigate efficacy of AHCHOS, its influencing factors, and effect on quality of life in these patients.
METHODS: This study enrolled 254 hospitalized child patients with LRTI and symptoms of mucoid sputum receiving AHCHOS.
RESULTS: Total cough of respiratory symptom (QS) score and QS scores of each subscale (cough, amount of sputum, difficulty in expectoration, and wheeling rale) on the 7th day (D7) were decreased than those at baseline (all P < 0.001). After multivariate logistic regression analysis, non parental guardian status (OR = 25.641, P = 0.020), respiratory rate (OR = 1.075, P = 0.019), and neutrophil percentage (OR = 1.034, P = 0.026) were independently related to higher possibility of absolute value of change of total QS score>5. Quality of life visual analog scale score on D7 was reduced than that at baseline (P < 0.001). Medication compliance was 98.00% on the 4th day, 92.68% on D7, 76.00% on the 14th day, and 75.95% on the 28th day. No adverse event occurred.
CONCLUSION: AHCHOS alleviates respiratory symptoms and improves quality of life with good safety in child patients with LRTI and symptoms of mucoid sputum, which is more beneficial for those with elevated respiratory rate, higher neutrophil percentage, and nonparental guardians.
METHODS: This study enrolled 254 hospitalized child patients with LRTI and symptoms of mucoid sputum receiving AHCHOS.
RESULTS: Total cough of respiratory symptom (QS) score and QS scores of each subscale (cough, amount of sputum, difficulty in expectoration, and wheeling rale) on the 7th day (D7) were decreased than those at baseline (all P < 0.001). After multivariate logistic regression analysis, non parental guardian status (OR = 25.641, P = 0.020), respiratory rate (OR = 1.075, P = 0.019), and neutrophil percentage (OR = 1.034, P = 0.026) were independently related to higher possibility of absolute value of change of total QS score>5. Quality of life visual analog scale score on D7 was reduced than that at baseline (P < 0.001). Medication compliance was 98.00% on the 4th day, 92.68% on D7, 76.00% on the 14th day, and 75.95% on the 28th day. No adverse event occurred.
CONCLUSION: AHCHOS alleviates respiratory symptoms and improves quality of life with good safety in child patients with LRTI and symptoms of mucoid sputum, which is more beneficial for those with elevated respiratory rate, higher neutrophil percentage, and nonparental guardians.